Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 1997

View Archived Issues

Delta-opioid receptor ligands reported by SmithKline Beecham

Agents specific for dopamine D3 receptors described by Neurogen

Dual D2/beta2 agonists disclosed by Astra

SKB reveals metallo-beta-lactamase inhibitors

Preclinical results for N-3389 in emesis

Inhibitors of 5alpha-reductase from Pharmacia & Upjohn

Hypolipidemic triterpenes claimed by Leo

Lp-PLA2 inhibitors from SmithKline Beecham

Pierre Fabre prepares agents with antidopaminergic/antiserotonergic effects

Positive results from preclinical studies with darifenacin

Synthelabo develops alternative to AChE inhibitors for AD

Roche describes TK inhibitors for recurrent HSV infection

Preclinical and clinical profile of Pharmacia & Upjohn's tolterodine

Positive clinical results for desirudin in the prevention of thromboembolism

Antisense oligonucleotides for RSV infection

Anti-HIV antisense oligonucleotides from Hybridon evaluated in SCID mice

BTS-67582 in diabetes

Agouron presents rhinovirus 3C protease inhibitor as promising clinical candidate

Potential HSV-2 vaccine described by Aviron

Clinical results for intravaginal dextrin sulfate gel

New ganciclovir derivative from Norsk Hydro for HSV infections

Nacystelyn promising alternative to NAC for lung antioxidant therapy

Alanex and ICOS enter small-molecule drug discovery collaboration

Biovail: Q1 1997 highlights

GelTex: Q1 1997 highlights

CytRx initiates new phase II trial of purified RheothRx

Amgen: Q1 1997 highlights

Oncor submits supporting data to FDA on breast cancer test

Hyal's Oralease receives Emergency Drug Release status in Canada

Pharmaceutical companies expand genomics research

ArQule and Genzyme collaborate on the discovery and development of novel drug candidates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...